Frontiers in Cancer Science 2023

Tikva Allocell presented two posters at the 15th Frontiers in Cancer Science conference, an AACR partner conference, held on 6-8 November 2023 at the NUS University Cultural Centre.

We were excited to present two posters at the 15th Frontiers in Cancer Science conference at the NUS University Cultural Centre.

In the first poster entitled “Off-The-Shelf Epstein-Barr Virus-Specific T cells Armored with B7-H3-Targeting Chimeric Antigen Receptors is an Effective and Safe Tumor-Agnostic Therapy for B7-H3 Positive Solid Malignancies”, Kar Wai discussed our in vitro and preclinical findings demonstrating high efficacy of Tikva Allocell’s B7H3.CAR EBVSTs pipeline product in targeting various B7-H3+ solid tumor types, and their dampened ability to cause cytokine release syndrome, a common and severe adverse event in CAR T cell therapy. In addition, we discovered that B7H3.CAR EBVSTs are able to target and reverse the immunosuppressive effects of myeloid-derived suppressor cells, which often hinder efficacy of immune-directed cancer therapies.

In the second poster entitled “Single Cell Profiling Reveals Unique TCR Repertoire and Transcriptomic Signatures of Epstein-Barr Virus-Specific T cells (EBVSTs) Armoured with Chimeric Antigen Receptors (CARs)”, Lindsay presented our efforts to more deeply understand the off-the-shelf CAR EBVST product through single cell sequencing. Based on gene expression analyses, we found that CAR EBVSTs appear to be more polyfunctional than their non-EBV-specific T cell counterparts bearing the same CAR. By scrutinizing T cell receptor (TCR) sequences of every cell, we found that CAR EBVSTs harbor a very EBV-focused set of TCRs, rendering them minimally reactive except possibly to EBV-infected cells, which may explain their greatly reduced killing of allogeneic cells and suitability as an off-the-shelf therapy.

Lindsay KUA, PhD

Senior Research Scientist

Lindsay Kua is a senior research scientist at Tikva Allocell. Over the course of her scientific career, she has worked with academics, clinicians, and industry partners both locally in Singapore and abroad on projects spanning the gut microbiome, intestinal immunology, and the tumour microenvironment.

Kar Wai TAN, PhD

Director, Pre-Clinical

Kar Wai is the Director of the Pre-Clinical Team at Tikva Allocell. She has a solid translational research experience spanning across Singapore Immunology Network, Singapore General Hospital, Euchloe Bio and Tessa Therapeutics, with key focus on cancer immunotherapeutics, cell therapy and preclinical drug development. She is also the inventor of 4 patents and key author on 17 publications.

Share the Post:

Related Posts